You are here

Roche

Roche vice chairman says short-term profit hunger 'destroyed the planet'

Yahoo/Reuters

Fri, 10/11/19 - 10:26 am

environmental concerns

Novartis' ligelizumab outperforms Roche's Xolair in chronic urticaria clearance

Pharmafile

Wed, 10/9/19 - 11:10 pm

clinical trials

chronic urticaria

Humira, Rituxan top list of U.S. drugs with biggest price increases -report

Yahoo/Reuters

Tue, 10/8/19 - 09:23 am

After more than a year, Gilead finds new chief medical officer

Biopharma Dive

Mon, 10/7/19 - 12:04 pm

Gilead Sciences

ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More

Xconomy

Tue, 10/1/19 - 10:29 am

PARP inhibitors

prostate cancer

Seattle Genetics

Roche gets FDA nod for Rituxan to treat children with two blood vessel disorders

Pharmaceutical Business Review

Mon, 09/30/19 - 12:09 pm

eosinophilic granulomatosis with polyangiitis

microscopic polyangiitis

Roche sets new deadline for Spark acquisition as divestiture speculation brews

Endpoints

Mon, 09/30/19 - 12:00 pm

Spark Therapeutics

ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win

Fierce Pharma

Sat, 09/28/19 - 04:49 pm

Roche-Spark deal review in U.K. unnerves M&A watchers—and they were spooked already

Fierce Pharma

Wed, 09/25/19 - 11:57 am

Spark Therapeutics

Roche AI Program Can Predict Progression of Diabetic Retinopathy

BioSpace

Tue, 09/24/19 - 07:11 pm

artificial intelligence

diabetic retinopathy

Roche Packs New FDA-Approved Test in Its Arsenal

Medical Devices and Diagnostics Industry

Sun, 09/22/19 - 10:59 pm

After touting Gazyva's potential in lupus, Roche nabs 'breakthrough' ahead of PhIII

Endpoints

Wed, 09/18/19 - 10:02 am

lupus nephritis

Roche and Celgene set for battle in acute myelogenous leukaemia

EP Vantage

Wed, 09/18/19 - 09:54 am

acute myeloid leukemia

ECTRIMS: Roche's Ocrevus, given early, cuts wheelchair risk by 42%

Fierce Pharma

Sun, 09/15/19 - 09:59 pm

multiple sclerosis

Renal Cell Carcinoma Space in Focus: Some Key Developments

Yahoo/Zacks.com

Sat, 09/14/19 - 11:18 am

renal cell carcinoma

As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo

Pharmaforum

Fri, 09/13/19 - 10:56 am

HER2-positive breast cancer

Roche's satralizumab cuts relapse risk in rare disease phase 3

Fierce Biotech

Thu, 09/12/19 - 10:37 am

neuromyelitis optica spectrum disorder

Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study

Pharmaceutical Business Review

Thu, 09/12/19 - 10:17 am

clinical trials

non-small cell lung cancer

FDA Approval of Roche Cancer Drug Confirms Beginning of New Oncology Era

Motley Fool

Wed, 09/11/19 - 12:46 pm

Pages